Pinned post
20 yrs ago, I had terminal #Cancer with no cure in sight. Read about my miracle! curetoday.com/community/mel-… #Retweet
Mel Mann, MBA, M.Ed
Verified account This account is verified. Learn more@MelDMann
World’s Longest Living Gleevec and TKI Survivor. 31 year terminal Cancer Survivor. Army Retired. True Medical Stories About Incredible People Everyday! ❤️
241K Following 476K Followers 37K Posts
Latest posts 5
Physical activity is one of the strongest modifiable factors linked to lower cancer risk.
Large observational studies and guidelines associate regular movement with reduced risk of several common cancers. It also supports recovery and quality of life for many people already diagnosed.
Start where you are. Even short walks count. Pair activity with the screenings your clinician recommends. Education only — not medical advice.
Large observational studies and guidelines associate regular movement with reduced risk of several common cancers. It also supports recovery and quality of life for many people already diagnosed.
Start where you are. Even short walks count. Pair activity with the screenings your clinician recommends. Education only — not medical advice.
“Patients with a devastating form of leukemia — chronic myeloid leukemia — could suddenly expect a normal life span.” — reflecting on Gleevec’s impact after its rapid FDA approval.
Brian Druker’s work shifted cancer treatment from non-specific chemotherapy toward highly targeted agents. That shift continues today. Education only — not medical advice.
Brian Druker’s work shifted cancer treatment from non-specific chemotherapy toward highly targeted agents. That shift continues today. Education only — not medical advice.
Phase 3 ARTEMIS-011 in relapsed/refractory osteosarcoma showed a clear progression-free survival gain.
The B7-H3-targeted antibody-drug conjugate risvutatug rezetecan produced a median PFS of 5.5 months versus 1.4 months with gemcitabine + docetaxel (HR 0.33). Disease control rate was 76% versus 33%.
Overall survival data are still maturing, but the early PFS signal is one of the strongest seen in this rare cancer in years. Education only — not medical advice.
The B7-H3-targeted antibody-drug conjugate risvutatug rezetecan produced a median PFS of 5.5 months versus 1.4 months with gemcitabine + docetaxel (HR 0.33). Disease control rate was 76% versus 33%.
Overall survival data are still maturing, but the early PFS signal is one of the strongest seen in this rare cancer in years. Education only — not medical advice.
Mel Mann was diagnosed with chronic myeloid leukemia in 1995 at age 37 and given three years to live.
No bone-marrow match was found. In 1998 he joined the phase 1 trial of imatinib (Gleevec). The drug controlled his disease. He is now among the longest-living people on targeted kinase inhibitors.
His story shows how one well-designed trial can rewrite a prognosis. Education only — not medical advice.
No bone-marrow match was found. In 1998 he joined the phase 1 trial of imatinib (Gleevec). The drug controlled his disease. He is now among the longest-living people on targeted kinase inhibitors.
His story shows how one well-designed trial can rewrite a prognosis. Education only — not medical advice.